KR860007207A - 페닐 카르바메이트 및 이것의 염을 제조하는 방법 - Google Patents

페닐 카르바메이트 및 이것의 염을 제조하는 방법 Download PDF

Info

Publication number
KR860007207A
KR860007207A KR1019860001491A KR860001491A KR860007207A KR 860007207 A KR860007207 A KR 860007207A KR 1019860001491 A KR1019860001491 A KR 1019860001491A KR 860001491 A KR860001491 A KR 860001491A KR 860007207 A KR860007207 A KR 860007207A
Authority
KR
South Korea
Prior art keywords
formula
compound
hydrogen
reacting
lower alkyl
Prior art date
Application number
KR1019860001491A
Other languages
English (en)
Other versions
KR940010764B1 (ko
Inventor
윈스톡 로진 마르타
코르브 마이클
타쉬마 지브
Original Assignee
프로테라 에이지
원본 미기재
이슘 리서치 디벨로프먼트 컴패니 오브더 헤브류 유니버시티 오브 예루살렘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860007207(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프로테라 에이지, 원본 미기재, 이슘 리서치 디벨로프먼트 컴패니 오브더 헤브류 유니버시티 오브 예루살렘 filed Critical 프로테라 에이지
Publication of KR860007207A publication Critical patent/KR860007207A/ko
Application granted granted Critical
Publication of KR940010764B1 publication Critical patent/KR940010764B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

내용 없음

Description

페닐 카르바메이트 및 이것의 염을 제조하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음 구조식(Ⅱ)화합물은 아미노화시키고 유리염기 형태 또는 약학적으로 허용될수 있는 염형태로 얻어진 구조식(I)화합물을 회수하는 것을 특징으로 하는 다음구조식(I)을 갖는 신규의 페닐 카르바메이트 화합물 또는 약학적으로 허용될 수 있는 이들의 염을 제조하는 방법.
    상기식에서, R1은 수소, 저급알킬, 사이클로헥실, 알릴 또는 벤질, R2는 수소, 메틸, 에틸 또는 프로필 또는 R1과 R2는 질소와 함께 부착되어 모르포리노 또는 피페리디노기를 형성하며, R3는 수소 또는 저급알킬, R4와 R5는 같거나 또는 다른 것이고 각기 저급알킬과 메타, 오르토 또는 파라위치의 디알킬아미노알킬 그룹이다.
  2. 제1항에 있어서, 구조식(Ⅱ)화합물을 이소시아네이트와 반응시키는 단계를 포함하는 R1이 수소인 구조식(I)화합물의 제조방법.
  3. 제1항에 있어서, 구조식(Ⅱ)화합물을 카르바모일할로게나이드와 반응시키는 단계를 포함하는 방법.
  4. 제3항에 있어서, 구조식(Ⅱ)화합물을 카르바모일클로라이드와 반응시키는 단계를 포함하는 방법.
  5. 제1항에 있어서, 디알킬아미노그룹이 메타위치이고 R4와 R5가 둘다 메틸인 화합물을 제조하는 방법.
  6. 활성제로서 구조식(I)의 화합물로 구성되는 중추신경계에서 항콜린에스테라제를 생성하도록 적용된 약학적 조성물.
  7. 제6항에 있어서, 구조식(I)의 화합물을 생리학적으로 허용될수 있는 담체와 혼합하는 단계를 구성되는 약학적 조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860001491A 1985-03-05 1986-03-04 페닐카르바메이트 및 이것의 염을 제조하는 방법 KR940010764B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL74497 1985-03-05
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (2)

Publication Number Publication Date
KR860007207A true KR860007207A (ko) 1986-10-08
KR940010764B1 KR940010764B1 (ko) 1994-11-11

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860001491A KR940010764B1 (ko) 1985-03-05 1986-03-04 페닐카르바메이트 및 이것의 염을 제조하는 방법

Country Status (25)

Country Link
US (1) US4948807A (ko)
EP (1) EP0193926B3 (ko)
JP (1) JPS61225158A (ko)
KR (1) KR940010764B1 (ko)
AT (1) ATE58130T1 (ko)
AU (1) AU595504B2 (ko)
CA (1) CA1284501C (ko)
CY (2) CY1748A (ko)
DE (2) DE3675408D1 (ko)
DK (1) DK172851B1 (ko)
ES (1) ES8801193A1 (ko)
FI (1) FI87197C (ko)
GR (1) GR860586B (ko)
HK (1) HK130293A (ko)
HU (1) HU201297B (ko)
IE (1) IE58838B1 (ko)
IL (1) IL74497A (ko)
LU (1) LU90312I2 (ko)
MY (1) MY137602A (ko)
NL (1) NL980031I2 (ko)
NZ (1) NZ215348A (ko)
PH (1) PH23325A (ko)
PL (1) PL146301B1 (ko)
PT (1) PT82127B (ko)
ZA (1) ZA861653B (ko)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
US5965571A (en) * 1996-08-22 1999-10-12 New York University Cholinesterase inhibitors for treatment of Parkinson's disease
IL130528A (en) 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
DE69725467T2 (de) * 1996-12-18 2004-07-22 Teva Pharmaceutical Industries Ltd. Phenylethylamin-derivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
EP0952826B1 (en) * 1997-01-17 2001-11-14 Takeda Chemical Industries, Ltd. Idebenone containing combination agent for treating alzheimer's disease
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
HUP0301794A3 (en) 2000-01-28 2011-04-28 Martek Biosciences Corp Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2140868A1 (en) * 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US7385076B2 (en) 2002-05-31 2008-06-10 Sun Pharmaceutical Industries Limited Process for the preparation of phenylcarbamates
BRPI0311780B8 (pt) 2002-06-14 2021-05-25 Toyama Chemical Co Ltd composição farmacêutica para melhorar a função cerebral
EP1558591B1 (en) 2002-10-07 2014-05-07 The Regents of The University of California Modulation of anxiety through blockade of anandamide hydrolysis
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
EP1689704A2 (en) * 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
WO2005051919A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
JP4954886B2 (ja) * 2004-11-08 2012-06-20 エムキュア ファーマシューティカルズ リミテッド （ｓ）−３−［（１−ジメチルアミノ）エチル］−フェニル−ｎ−エチル−ｎ−メチル−カルバミン酸の効率的製造方法
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CA2650711A1 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
EP2054373B1 (en) * 2006-08-17 2010-06-30 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
CA2677241A1 (en) 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
WO2008124969A1 (fr) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Méthode de préparation de rivastigmine et de ses intermédiaires
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
WO2010023535A1 (en) 2008-08-25 2010-03-04 Jubilant Organosys Limited A process for producing (s)-3-[(1-dimethylamino)ethyl] phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
US8852900B2 (en) 2010-06-17 2014-10-07 Codexis, Inc. Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
FI87197C (fi) 1992-12-10
ES552627A0 (es) 1988-01-01
IL74497A0 (en) 1985-06-30
DK99186D0 (da) 1986-03-04
EP0193926A3 (en) 1987-05-13
AU5428486A (en) 1986-09-11
GR860586B (en) 1986-07-07
CY1748A (en) 1994-06-03
AU595504B2 (en) 1990-04-05
CA1284501C (en) 1991-05-28
DK99186A (da) 1986-09-06
LU90312I2 (fr) 1999-01-06
PH23325A (en) 1989-07-14
IE860558L (en) 1986-09-05
JPH0255416B2 (ko) 1990-11-27
NL980031I1 (nl) 1999-01-04
DE3675408D1 (de) 1990-12-13
MY137602A (en) 2009-02-27
EP0193926B3 (en) 2010-04-28
HU201297B (en) 1990-10-28
CY2004004I2 (el) 2009-11-04
FI860914A (fi) 1986-09-06
EP0193926B1 (en) 1990-11-07
EP0193926A2 (en) 1986-09-10
FI87197B (fi) 1992-08-31
DK172851B1 (da) 1999-08-16
PL146301B1 (en) 1989-01-31
NL980031I2 (nl) 1999-03-01
HUT41718A (en) 1987-05-28
IL74497A (en) 1990-02-09
FI860914A0 (fi) 1986-03-04
PT82127B (pt) 1988-07-01
CY2004004I1 (el) 2009-11-04
NZ215348A (en) 1990-04-26
ZA861653B (en) 1987-10-28
HK130293A (en) 1993-12-03
JPS61225158A (ja) 1986-10-06
US4948807A (en) 1990-08-14
KR940010764B1 (ko) 1994-11-11
PT82127A (en) 1986-04-01
DE19875046I1 (de) 2003-09-04
IE58838B1 (en) 1993-11-17
ATE58130T1 (de) 1990-11-15
ES8801193A1 (es) 1988-01-01

Similar Documents

Publication Publication Date Title
KR860007207A (ko) 페닐 카르바메이트 및 이것의 염을 제조하는 방법
KR900007837A (ko) 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법
KR870006016A (ko) N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법
KR920004338A (ko) 치환된 발린아미드 유도체
SE8800731L (sv) Fenylkarbamat
KR830007514A (ko) 두고리 화합물의 제조방법
KR880002817A (ko) 히드록시알킬 카르바메이트와 그 제조방법 및 용도
KR900003163A (ko) 시클로헥산 유도체
KR910014395A (ko) 신규 화합물
ES557196A0 (es) Un procedimiento para la preparacion de amidas de aminoacido con actividad antitumoral
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
KR940003953A (ko) 1. 4-벤조디옥산 유도체
KR850006936A (ko) 티오페닐우레아의 제조방법
KR850700108A (ko) 항종양 의약 조성물 및 그의 제조 방법
DE3464244D1 (de) 1-(4&#39;alkylsulfonylphenyl)-2-amino-1,3-propanediol n-substituted derivatives
KR830004217A (ko) 약학적 활성이 있는 펩타이드
PT84680B (pt) Processo para a preparacao de derivados de 1,5-benzotiazepina e de composicoes farmaceuticas que os contem
ES8401946A1 (es) Procedimiento para la preparacion de sulfonilureas.
KR920701144A (ko) 아미노산 유도체
EP0255366A3 (en) Nitrogen- and sulfur-containing lipid compound, their production and use
ZA845930B (en) 1-(4&#39;-alkylthiophenyl)-2-amino-1,3-propanediol n-substituted derivatives
KR840004420A (ko) N-(1,3-디티올린-2-알리덴)아닐린 유도체의 제조방법
ES8504754A1 (es) Procedimiento para preparar la n-(3-trifluorometil fenil)-n-propargil-piperazina.
KR860001815A (ko) 옥타하이드로-옥사졸로[4,5-g]퀴놀린의 제조방법
ES8609207A1 (es) Procedimiento para la preparacion de derivados de feniletilamina.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051111

Year of fee payment: 12

EXPY Expiration of term